Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Recruiting

Phase 2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Sponsor:

Gilead Sciences

Code:

NCT03547973

Conditions

Metastatic Urothelial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan-hziy

Pembrolizumab

Cisplatin

Avelumab

Zimberelimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-14. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2025-04-15.